BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 15755280)

  • 21. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group.
    Borowitz MJ; Pullen DJ; Winick N; Martin PL; Bowman WP; Camitta B
    Cytometry B Clin Cytom; 2005 Nov; 68(1):18-24. PubMed ID: 16184615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
    Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Detection of minimal residual disease in B lineage acute lymphoblastic leukemia by 4-color flow cytometry].
    Liu YR; Wang H; Chang Y; Cheng YF; Fu JY; Zhang LP; Liu GL; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):327-31. PubMed ID: 16185473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
    J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
    DiGiuseppe JA; Fuller SG; Borowitz MJ
    Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
    van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
    Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of minimal residual disease in acute leukemia patients.
    van Dongen JJ; Szczepański T; de Bruijn MA; van den Beemd MW; de Bruin-Versteeg S; Wijkhuijs JM; Tibbe GJ; van Gastel-Mol EJ; Groeneveld K; Hooijkaas H
    Cytokines Mol Ther; 1996 Jun; 2(2):121-33. PubMed ID: 9384697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia.
    Szczepański T; Flohr T; van der Velden VH; Bartram CR; van Dongen JJ
    Best Pract Res Clin Haematol; 2002 Mar; 15(1):37-57. PubMed ID: 11987915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Detection of clonal immunoglobulin and T-cell receptor gene rearrangements in newly diagnosed adult patients with acute lymphoblastic leukemia by using multiplex PCR protocols].
    Yao L; Chen ZX; Cen JN; Liang JY; He J; Qi XF; Shen HJ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):676-8. PubMed ID: 19176062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance.
    Ruiz-Argüelles GJ; Fernández-Lara D; Estrada-Gómez R; Manzano C; Ruiz-Delgado GJ; Pérez-Romano B; Ruiz-Argüelles A
    Lab Hematol; 2007; 13(1):22-6. PubMed ID: 17353179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia.
    Björklund E; Mazur J; Söderhäll S; Porwit-MacDonald A
    Leukemia; 2003 Jan; 17(1):138-48. PubMed ID: 12529671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Minimal residual disease in childhood acute lymphoblastic leukaemia quantified by aspirate and trephine: is the disease multifocal?
    Sykes PJ; Brisco MJ; Hughes E; Snell LE; Dolman G; Neoh SH; Peng LM; Toogood I; Venables WN; Morley AA
    Br J Haematol; 1998 Oct; 103(1):60-5. PubMed ID: 9792290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Minimal residual disease in childhood acute leukemias].
    Pawińska K; Balwierz W; Baran J
    Przegl Lek; 2006; 63(1):41-3. PubMed ID: 16892899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis.
    van der Velden VH; Wijkhuijs JM; Jacobs DC; van Wering ER; van Dongen JJ
    Leukemia; 2002 Jul; 16(7):1372-80. PubMed ID: 12094263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-time quantification of TEL-AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic leukaemia. Comparison with antigen receptor-based MRD quantification methods.
    Taube T; Eckert C; Körner G; Henze G; Seeger K
    Leuk Res; 2004 Jul; 28(7):699-706. PubMed ID: 15158091
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of minimal residual disease in acute leukemia.
    van der Velden VH; Boeckx N; van Wering ER; van Dongen JJ
    J Biol Regul Homeost Agents; 2004; 18(2):146-54. PubMed ID: 15471219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Development of a new strategy for minimal residual disease monitoring in children with B-precursor acute lymphoblastic leukemia].
    Bonjean B; Grollet L; Visentin E; Sigaux F; Cayuela JM
    Ann Biol Clin (Paris); 2004; 62(4):465-70. PubMed ID: 15297244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: multi-institutional collaborative study in Japan.
    Imashuku S; Terui K; Matsuyama T; Asami K; Tsuchiya S; Ishii E; Kawa K; Kosaka Y; Eguchi H; Tsuchida M; Ikuta K; Kato S; Koizumi S; Okamura J; Morimoto A; Hibi S; Hamaoka K;
    Bone Marrow Transplant; 2003 Jun; 31(12):1127-35. PubMed ID: 12796792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology.
    Cazzaniga G; Biondi A
    Haematologica; 2005 Mar; 90(3):382-90. PubMed ID: 15749670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of four MRD markers in MRD-based treatment strategy for childhood acute lymphoblastic leukemia.
    Sawada A; Sakata N; Kishimoto T; Higuchi B; Koyama M; Kondo O; Sato E; Okamura T; Yasui M; Inoue M; Yoshioka A; Kawa K
    Leuk Res; 2009 Dec; 33(12):1710-3. PubMed ID: 19596431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.